Tibet Aim Pharm.Inc(002826) 4 disclosed in the annual report of 2021 on the evening of April 21 that the sales revenue of the company’s main products such as Aotian pingmiglitol tablets, Xintong Gualou skin injection, retinoline Domperidone Tablets, beiyiping montmorillonite powder, meixiaodan Hongjinxiaojie tablets increased to varying degrees, and the annual business revenue was 725459100 yuan, an increase of 20.38% over the same period of the previous year; The net profit attributable to shareholders of listed companies was 424765 million yuan, an increase of 3.37% over the same period last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 386346 million yuan, a year-on-year increase of 21.29%. The company plans to distribute a cash dividend of 1.00 yuan (including tax) to all shareholders for every 10 shares.
During the reporting period, the company’s main business varieties can be divided into two categories: self-produced drugs and third-party cooperative drugs. Among them, there are mainly five kinds of self-produced drugs, namely miglitol tablets (aotianping), montmorillonite powder (beiyiping), Yi medicine ancient prescription Hongjin Xiaojie tablets (meixiaodan), Domperidone Tablets (vidolin) and aceclofenac enteric coated tablets (vipofen). Most of them are characteristic drugs that fill the gap in China’s market or have few competitive products, and all of them are products in the 2021 national medical insurance catalogue. In addition, the company also produces generic products with strong market competitiveness, such as Azithromycin Capsules and Loratadine Tablets. The miglitol raw materials and aceclofenac raw materials produced by vior pharmaceutical, a wholly-owned secondary subsidiary of the company, have advantages in production process and quality control, and some raw materials have been sold abroad. Among them, aceclofenac raw materials have become the main supplier of the raw materials in the Chinese market, accounting for most of the market share.
The third-party cooperative drugs include Gualou PI injection (Xintong), nalmefene hydrochloride injection (yimeifen), cabetoxin injection (Yiming xinnuoshu), digoxin injection (Chile), multivitamins for injection (12) (Weimeijia), sodium acetate ringer injection (Huineng), Dazhu Hongjingtian injection, ligustrazine phosphate for injection (ficoan), polymyxin sulfate B for injection (Yale) A variety of trace element injection (weihengsu) and other products, including Gualou PI injection (Xintong) and nalmefene hydrochloride injection (yimeifen) are products developed by the company in cooperation with well-known pharmaceutical enterprises. The company and the manufacturer jointly develop new drug varieties. The manufacturer obtains the production registration approval and is responsible for production. The company is responsible for drug promotion.
In terms of R & D, during the reporting period, Tibet Aim Pharm.Inc(002826) completed the filing of lysiprofen API and the registration and application of lysiprofen injection. By the end of the reporting period, the project was in the review status; The company’s montmorillonite API project has passed the technical review of the evaluation center of the State Food and drug administration.
